Universal Beteiligungs und Servicegesellschaft mbH Has $30.18 Million Stake in Natera, Inc. $NTRA

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 131,702 shares of the medical research company’s stock after selling 8,100 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Natera worth $30,184,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. TABR Capital Management LLC bought a new position in Natera during the fourth quarter worth $236,000. TD Waterhouse Canada Inc. bought a new position in Natera during the fourth quarter worth $62,000. Krilogy Financial LLC boosted its position in Natera by 2.8% during the fourth quarter. Krilogy Financial LLC now owns 8,447 shares of the medical research company’s stock worth $2,039,000 after purchasing an additional 228 shares during the period. Earned Wealth Advisors LLC boosted its position in Natera by 22.0% during the fourth quarter. Earned Wealth Advisors LLC now owns 2,382 shares of the medical research company’s stock worth $546,000 after purchasing an additional 430 shares during the period. Finally, First Horizon Corp boosted its position in Natera by 7.3% during the fourth quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock worth $213,000 after purchasing an additional 63 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the transaction, the chief financial officer owned 52,120 shares of the company’s stock, valued at approximately $11,874,499.60. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 85,299 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the transaction, the chief executive officer directly owned 127,881 shares of the company’s stock, valued at approximately $29,504,704.32. The trade was a 40.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 138,257 shares of company stock worth $31,468,797 in the last ninety days. Insiders own 5.63% of the company’s stock.

Natera Trading Down 3.2%

Shares of NASDAQ NTRA opened at $201.14 on Friday. The company has a market cap of $28.51 billion, a price-to-earnings ratio of -131.46 and a beta of 1.68. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The stock has a 50-day moving average price of $202.94 and a two-hundred day moving average price of $212.66.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the previous year, the firm earned ($0.41) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on NTRA. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Wells Fargo & Company boosted their target price on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. William Blair assumed coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, Wall Street Zen raised shares of Natera from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.